# Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers

> **NCT05525780** · PHASE1 · COMPLETED · sponsor: **G2GBio, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** GB-5001
- **DRUG:** Placebo
- **DRUG:** Oral cohort

## Key facts

- **NCT ID:** NCT05525780
- **Lead sponsor:** G2GBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-26
- **Primary completion:** 2023-06-02
- **Final completion:** 2023-06-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525780, "Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05525780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*